View
214
Download
0
Category
Preview:
Citation preview
A Unique Indian Public-Private Partnership
New Millennium Indian New Millennium Indian Technology Leadership Technology Leadership
InitiativeInitiative
Dr. D. Yogeswara RaoHead
Technology Networking and Business Development DivisionCouncil of Scientific & Industrial Research
New Delhi
OBJECTIVE OBJECTIVE
To secure for India, a To secure for India, a leadershipleadership positionposition in niche in niche areas, based onareas, based on technology technology throughthrough TEAM INDIA TEAM INDIA efforteffort
DISTINCTIVE FEATURES• Proactive• Project development through national consultation &
churning• Investment in areas where India has a sustainable
comparative advantage • Invitation (not application) to the best• Close monitoring & foreclosure• Govt. / CSIR seeks no direct returns • Equitable IPR sharing
PROJECTS PROJECTS
•• Nationally evolved Nationally evolved
•• InIndustry originateddustry originated
THE PRESENT STATUS
PROJECTSPROJECTS :: 3333
PARTNERSPARTNERS :: 222 222
(167 PUBLIC + 55 PRIVATE)(167 PUBLIC + 55 PRIVATE)
OUTLAYOUTLAY :: Rs. 2.2 billionRs. 2.2 billion
DATE OF START OF THE PROGRAMME : MARCH 2001
India so far operated here
NMITLI
High Low
Low
Market Certainty
Tech
nolo
gy C
erta
inty
POSITIONING NMITLI : PROJECTS
NMITLI
Concept Proving
TDB/INDUSTRY/VC
Prototyping
Pilot Plant
Pre-Commercialization
Financing Commercialization through Banks
1 10 100 1000
NMITLI : Multiplier effect in the Technological Innovation and Commercialization Chain
Relative Financial Scale
ICICI/IFCI/TDB
0
1
2
3
4
5
6
7
Agric
ultu
re &
Plan
tBi
otec
hnol
ogy
Biot
echn
olog
y
Bioi
nfro
amtic
s
Dru
g &
Phar
mac
eutic
als
Che
mci
als
Mat
eria
ls
IT a
ndC
omm
unic
atio
n
Ener
gy
Mis
celle
nous
Area
Num
ber
Number
SPREAD OF PROJECTS
HEALTH SECTOR
NMITLI LAYING ITS BETS ON
• Diseases of the Poor
• Leveraging Traditional Medicine
• Special niches based on Indian strengths
• Special Indian Needs
LATENT M TUBERCULOSIS : NEW TARGETS, DRUG DELIVERY SYSTEMS, BIO-ENHANCERS AND THERAPEUTICS
Special Indian niches/needs• Large disease burden
• Availability of high level knowledge base
• Lack of interest by MNCs / TNCs
Objectives:• To improve current treatment of TB by further shortening the total duration of the
treatment
• To provide effective treatment for latent tuberculosis infection
• To improve treatment of patients with multi-drug resistance (MDR)
• To ensure cost effectiveness and safety of the drug molecule developed
Strategy:• Identification of new drug targets
• Development of new therapeutics using novel chemistry
Contd….
• Application of bio-enhancers as an adjunct to chemotherapy
• Development of new drug delivery systems
Status:• Discovery of a new drug molecule, first in last 40 years
• Reduces treatment duration from 6 months to 2 months (in combination)
• IND cleared and clinical trials planned
• 4 new drug targets are being validated
• Efficacy of a new bioenhancer (across all the 4 drugs being tested)
• Dry powder inhalation delivery system for TB drugs- preclincialstudies are underway
LATENT M TUBERCULOSIS : Contd…
‘Team India’ effort involves 12 institutional partners and one industrial partner
PSORIASIS
• A single plant based oral herbal formulation identified• Reverse pharmacology approach adopted• IND filed in December 2003; Cleared in March 2004• Phase I clinical trials – completed • Phase II clinical trials planned
Status :
Project network involves two institutional partners and one industrial partner
Stimulants:• Leveraging Indian traditional knowledge• Causes and pathogenesis not-clearly understood• No preventive/ curative therapy exists• Large affected population (ww 1-2%)• Estimated market size (US $ 3-4 b)
India has global patent positioning
Bio-molecule free from pre-pro lysostaphin- a niche
High global market potential for both human and dairy applications
Status:Large scale production of >99% protein using novel downstream process
Drug related characterization and efficacy studies completed
Regulatory studies are underway
IND filing scheduled for March, 2005
LYSOSTAPHIN : NOVEL BIOTECH THERAPEUTIC MOLECULE
Special Indian niches/needs
NEW TARGETS AND MARKERS FOR CANCER USING GENOMICS & PROTEOMICS
• Large patient pool
• Need for early diagnostic markers
• Excellent market potential
Objectives: • A multi-centric joint effort between clinical oncologists, surgeons,
pathologists, molecular biologists, geneticists & epidemiologists from a network of 3 institutions, 3 hospitals & one industry
• Types of Cancer being studied are glioma, oral cancer & gall bladder
• Differential gene expression studies directed towards a) cell cycle control genes b) signal transduction pathway genes c) biochemical global gene expressions and d) apoptosis related genes.
• Proteomics is used to compare the proteomic profile of a cancer cell in comparison to a normal cell.
Special Indian niches / needs
Contd..
Status:
• Several genes & proteins are identified in glioma and head & neck
• Validation of identified genes and proteins on larger sample size is underway
• Development of micro-chip for diagnostic/ prodiagnosticapplication is underway
Cancer: A team effort of clinical oncologists, surgeons, pathologists, molecular biologists
BLLOD AND TISSUE BANKSAMPLE COLLECTION, CHARACTERIZATION
AND DOCUMENTATION
RGCI- DABURBRAIN, GALL BLADDER
MANIPAL HOSP.BRAIN
TMCHEAD & NECK; GALL BLADDER
GENOMICS AND PROTEOMICS
GENOMICSIISc
PROTEOMICSCCMB
GENOMICSCCMB
DATA DATA DATA
DATA INTEGRATIONTARGET, MARKER IDENTIFICATION AND VALIDATION
CCMB, IISc, DABUR, TMC, SSIMS, RGCIIPR
MARKETABLE PRODUCTDABUR
Status:• Passport data prepared for herbs used
• Raw materials & finished products standardized with modern analytical tools
• Limited toxicity studies completed
• Phase 2(a) studies – Completed for Arthritis; At advanced stage for other two
• Selected preclinical studies are underway
• Clinical studies, phase 2 and 3 are being planned
NOVEL HERBAL THERAPEUTICS FOR DEGENERATIVE DISORDERS
Objective• Scientific validation of poly-herbal Ayurvedic formulations for Arthritis,
Hepatocellular protection and Diabetes following reverse pharmacology
Special Indian niches/needs • Leveraging Indian traditional medicinal knowledge
• No effective treatment in modern medicine
Involves 18 institutional and 8 industrial partners
Special Indian niches/needs • Need for a low-cost decentralized diagnostic methods for early intervention • Potentially great social impact• Large patient pool• Availability of cutting edge scientific knowledgebase
Objectives: • Devise a microchip containing the responsible genes for glaucoma and infectious
eye-diseases to facilitate an easy and rapid diagnosis.
Project Components:
- Inherited eye diseases (glaucoma)- Infectious eye diseases- Low vision enhancement devices
Status :• Short listing of candidate genes and pathogens was accompolished• Validation of candidate genes on larger population groups is underway
EYE AND VISION
A network of 13 Research Institutions and 3 Industrial Partners
ASHWAGANDHAINDIAN TRADITIONAL MEDICINAL PLANT
Special Indian niches/needs• Ashwagandha comparable to Ginseng• Used in over 200 traditional medicinal formulations• Potential competitor to ginseng with market valued at US $5 b
Objectives:• Positioning Ashwagandha in global herbal market through
systematic scientific validation
Status:• Over 150 accessions collected from all over India and
chemoprofiled• Contrasting chemotypes identified • Pharmacological studies of selected plants underway
Indian niches/needs• Excellent expertise in software & Biotechnology• Low cost competitive alternative to the high cost imported software
needed
Salient Features:• More comprehensive than existing software suites• Will run on variety of platforms including PC• Highly modular structure• Comprises 8 major components, 58 sub-modules, 165 individual
algorithms• NMITLI brings together the distinctive knowledge segments as
‘Team India’ (21 Research Institutions and 3 Industrial Partners)
BIO-SUITE A VERSATILE, PORTABLE SOFTWARE SUITE FOR BIOINFORMATICS
Software was launched in ‘Bio’ at San Francisco (June 2004) & by President, India in Hyderabad (July 2004)
CONCLUSIONS
• NMITLI successful in launching India’s largest PPP in post independent India
• Sea change in thinking – from imitation to innovation
• Revising ‘bar’ on performance & delivery
• Early success of NMITLI influencing other funding agencies to replicate NMITLI models
Recommended